Terminated PHASE2 INTERVENTIONAL 4-arm NCT01937130

Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF

A Placebo-Controlled, Multicenter, Double-Blind, Randomized, Pharmacokinetic and Pharmacodynamic Trial of IDN-6556 in Subjects With Acute-on-Chronic Liver Failure

Sponsor: Conatus Pharmaceuticals Inc.

Conditions Acute Alcoholic Hepatitis Acute Liver Failure Acute on Chronic Hepatic Failure Liver Cirrhosis

Interventions IDN-6556 Placebo

Updated 8 times since 2017 Last updated: Mar 28, 2016 Started: Sep 30, 2013 Primary completion: Jan 31, 2015 Completion: Feb 28, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Data needs met

Other terminated trials from Conatus Pharmaceuticals Inc.

More terminations from Conatus Pharmaceuticals Inc.

Other Acute Alcoholic Hepatitis trials with similar outcome

Browse all Acute Alcoholic Hepatitis trials

This PHASE2 trial investigates Acute Alcoholic Hepatitis and Acute Liver Failure and is currently terminated or withdrawn. Conatus Pharmaceuticals Inc. leads this study, which shows 8 recorded versions since 2013 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Sep 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Conatus Pharmaceuticals Inc.

Data source: Conatus Pharmaceuticals Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Basildon, United Kingdom , Birmingham, United States , Blackpool, United Kingdom , Bristol, United Kingdom , Dundee, United Kingdom , Glasgow, United Kingdom , Jackson, United States , Kansas City, United States , La Jolla, United States , Leicester, United Kingdom and 15 more locations